Q3 Sales Slip 2.1% but Adjusted EBITDA Jumps to $13.4M; Guidance Reaffirmed
SKIN is trading near its 52-week low of $9.68 (6.9% above the low).
Summary
Q3 net sales fell 2.1% to $69.2 million as delivery system placements dropped to 798 from 875, but consumables returned to growth at $50.4 million and adjusted EBITDA rose to $13.4 million from $8.9 million a year ago. Gross margin expanded to 68.2% from 64.6%, and the net loss narrowed to $0.9 million from $11.0 million, helped by lower operating spend. The company retired the remaining $103.2 million of its 2026 Notes on September 30, leaving roughly $112 million in cash. Management guided FY2026 to $281-$287 million in net sales and $48-$50 million in adjusted EBITDA, citing continued sales pressure offset by cost discipline. The 1-for-20 reverse split took effect October 14, so all per-share figures here are post-split. The earnings call is at 4:30 p.m. ET today.
At the time of this announcement, SKIN was trading at $10.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.3M. The 52-week trading range was $9.68 to $34.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.